JAN 20, 2019 04:13 PM PST

Multiple sclerosis treatments hold long-term benefits

WRITTEN BY: Nouran Amin

An international study, led by the Clinical Outcomes Research unit (CORe) at Royal Melbourne Hospital and University of Melbourne, concludes the importance of early treatments of multiple sclerosis (particularly within the first five years of onset) holds extensive long-term benefits.

Learn more about Multiple Sclerosis (MS):

The study was the first to provide evidence that current drug treatments delay the progression of multiple sclerosis (MS) into its secondary stage which is described by an ongoing increase of disability involving the worsening of physical and mental capacity as well as the reduced quality of life. The crucial need to delay the progression represents an important outcome for individuals living with multiple sclerosis.

The research generated data from 1555 patients at 68 neurological clinics across 21 countries and highlighted the importance to treat MS pro-actively.

Multiple sclerosis is a condition characterized by areas of damage on the brain. This damage affects the covering that protects nerves (the myelin sheath).

Credit: NIH Genetics Home Reference

"People who converted from relapsing MS to secondary progressive MS experience gradual and mostly irreversible worsening of disability,” said Associate Professor and head of the MS Service at The Royal Melbourne Hospital and CORe at the University of Melbourne, Tomas Kalincik."Most of the therapies that we use to treat MS have no effect once people have converted to secondary progressive MS. This study shows us how important it is to treat relapsing MS early and pro-actively," Associate Professor Kalincik said.

Results of the study, in collaboration with the University of Cambridge, were published in the international medical journal, JAMA. Associate Professor Kalincik believes that the results are reassuring neurologists and patients with MS. He states, "This study shows that the therapies they have been treated with for many years, significantly improve the quality of their lives over the long-term.”

Source: The Royal Melbourne Hospital

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 13, 2018
Drug Discovery
NOV 13, 2018
Clinical Trial Drug For a Rare Neurodegenrative Disease Proven Unsuccessful
Niemann-Pick type C (NPC) is a rare and fatal neurodegenerative disease. Symptoms of the condition include loss of balance, difficulty swallowing, seizures...
NOV 15, 2018
Drug Discovery
NOV 15, 2018
A Subclass of Anti-Aging Compounds Serves as Alzheimer's Drug Candidates
In a publication in Trends in Pharmacological Sciences, a subclass of anti-aging compounds, called geroneuroprotectors (GNPs), have been identified in rese...
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Treating Restless Leg Syndrome (RLS)
A common condition of the nervous system, Restless Leg Syndrome (RLS) is the overwhelming urge to move the legs. Usually unpleasant symptoms, many RLS pati...
NOV 23, 2018
Cannabis Sciences
NOV 23, 2018
Rimonabant: A Cautionary Tale for Targeting the Endocannabinoid System
The evidence that the endocannabinoid system (ECS) is intimately involved in food intake has been steadily increasing. Thus, in attempts to treat obesity,...
DEC 13, 2018
Drug Discovery
DEC 13, 2018
First Non-Opioid Drug?
In a study published in the medical journal—PAIN, a non-opioid drug compound discovered by researchers from the National Institute of Health (NIH)&md...
JAN 07, 2019
Drug Discovery
JAN 07, 2019
First-in-Human Trial of Senolytic Drugs
According to a study published in the journal EBioMedicine, the very first results on the treatment of a deadly age-related disease in human patients using...
Loading Comments...